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Large amounts of dead and dying cells are produced during cancer therapy and allograft
rejection. Depending on the death pathway and stimuli involved, dying cells exhibit diverse
features, resulting in defined physiological consequences for the host. It is not fully under-
stood how dying and dead cells modulate the immune response of the host. To address
this problem, different death stimuli were studied in B16F10 melanoma cells by regulated
inducible transgene expression of the pro-apoptotic active forms of caspase-3 (revCasp-
3), Bid (tBid), and the Mycobacterium tuberculosis-necrosis inducing toxin (CpnTCTD). The
immune outcome elicited for each death stimulus was assessed by evaluating the allo-
graft rejection of melanoma tumors implanted subcutaneously in BALB/c mice immunized
with dying cells. Expression of all proteins efficiently killed cells in vitro (>90%) and dis-
played distinctive morphological and physiological features as assessed by multiparametric
flow cytometry analysis. BALB/c mice immunized with allogeneic dying melanoma cells
expressing revCasp-3 or CpnTCTD showed strong rejection of the allogeneic challenge. In
contrast, mice immunized with cells dying either after expression of tBid or irradiation with
UVB did not, suggesting an immunologically silent cell death. Surprisingly, immunogenic
cell death induced by expression of revCasp-3 or CpnTCTD correlated with elevated intra-
cellular reactive oxygen species (ROS) levels at the time point of immunization. Conversely,
early mitochondrial dysfunction induced by tBid expression or UVB irradiation accounted for
the absence of intracellular ROS accumulation at the time point of immunization. Although
ROS inhibition in vitro was not sufficient to abrogate the immunogenicity in our allo-
immunization model, we suggest that the point of ROS generation and its intracellular
accumulation may be an important factor for its role as damage associated molecular
pattern in the development of allogeneic responses.
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INTRODUCTION
The appearance of cell death during disease therapy is a two-
pronged sword. On one hand, cell death is desirable during cancer
treatment in order to control malignant cell growth in the patient.
On the other hand, excessive cell death should be avoided during
transplantation to allow the grafted cells to survive in a foreign
host. In the latter case, a considerable number of stresses are
involved and several kinds of injuries may additionally compro-
mise tissue viability, leading to progressive graft dysfunction and,
eventually, also to graft loss (1, 2).
Furthermore, the mechanism and type of cell death might
profoundly affect the reaction of the host toward surviving
cells, making the situation more complex. Apoptosis, necrosis,
autophagy, necroptosis, and other processes have been reported
as common cell death mechanisms observed in vivo dur-
ing therapies. However, how these types of cell death mod-
ulate interactions of the dying and dead cells with the
immune system remains elusive. Depending on the immune
response elicited, it is possible to distinguish between cases
of cell death able to induce immunogenicity (immunogenic
cell death) and those inducing immune tolerance or unre-
sponsiveness (tolerogenic/silent cell death) (3, 4). Dying cells
can exhibit completely different characteristics and immuno-
logical features. To understand these differences, an accurate
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characterization of the features, types, and phases of cell death
is required.
The latter has become especially important in the context of
diseases like cancer where conventional treatments (e.g., radia-
tion and chemotherapy) are based on the massive induction of
tumor cell death. In such cases, the immune system is prone to be
decisive for tumor fate. Because the guidelines for drug screening
in antineoplastic therapies require evaluation of human tumors
xenotransplanted into immune-compromised mice (5), the role of
the immune system has been neglected (6), making studies focused
on the interplay between immune system and dying cells neces-
sary. Modern anti-cancer therapies aim at inducing immunogenic
cancer cell death. However, there are a plethora of factors involved
in this process that have to be revisited and reassessed carefully.
These include intrinsic cell immunogenicity, the nature of the
initial death stimulus, the type of damage associated molecular
patterns (DAMPs) released, the clearance capacity of the affected
tissue for dying and dead cells, and the respective death pathway.
Considering the large number of cytotoxic drugs currently used in
the treatment of neoplastic diseases, much information is missing
to predict the anti-tumor response of the host reliably.
In this study, we showed how different mechanisms and types
of cell death, induced by different stimuli, affect the outcome of
allogeneic tumor transplants in BALB/c immune-competent mice.
Additionally, a morpho-physiological characterization of dying
and dead cells, based on a multiparametric flow cytometry analy-
sis, was assessed. A murine allograft model allowed evaluation of
the immune response in vivo. The results of this work may have
important implications for both cancer therapy and procedures
for experimental allotransplantation.
MATERIALS AND METHODS
REAGENTS AND MOLECULAR PROBES
Dulbecco’s modified eagle’s medium (DMEM), fetal bovine
serum (FBS), G418, penicillin–streptomycin, and glutamine
were from Gibco-Invitrogen. Recombinant chicken annexin A5
(AxA5) was purchased from Responsif. The FluoroTag fluores-
cein isothiocyanate (FITC) conjugation kit was from Sigma-
Aldrich, the 1,10,3,3,30,30-hexamethylindodicarbocyanine iodide
dye [DiIC1(5)], Hoechst 33342, Lipofectamine™ 2000, and
puromycin dihydrochloride were from Invitrogen. Propidium
iodide (PI) was obtained from Amersham Biosciences. Doxycy-
cline hydrochloride and trypsin–EDTA solution were purchased
from Sigma-Aldrich. Ringer’s solution was from Delta Select.
The caspase3 inhibitor z-DEVD-fmk, the caspase-9 inhibitor Ac-
LEHD-cmk, and the general caspase inhibitor z-VAD-fmk were
purchased from Bachem.
CELL LINES AND CULTURE CONDITIONS
The C57BL/6 mouse-derived melanoma cell line B16F10 bear-
ing the haplotype H2b was purchased from ATCC (#CRL-6475)
and propagated in DMEM supplemented with 10% FBS and
penicillin–streptomycin (D10) at 37°C in a 5% CO2 atmosphere.
For the morpho-physiological characterization by flow
cytometry, B16F10 cells were cultured in 24-well plates at
100,000 cells/2 ml D10 and harvested at the time points indi-
cated. Harvesting was performed as follows: supernatants con-
taining dead cells were harvested into polypropylene tubes. A
trypsin–EDTA solution was added to the wells for 10–15 min
at room temperature to detach the remaining adherent cells.
Thus, detached cells were collected by adding D10 and combined
with their corresponding supernatant fraction. Finally, cells were
centrifuged at 300 g for 5 min, resuspended in 500µl D10 medium.
GENERATION OF STABLE Tet-CONTROLLED SUICIDE CELL LINES
The cell lines B16F10-644, B16F10-tBid, and B16F10-revCasp-3
have been described (7). The parental cell line B16F10-644 was
transfected with the AhdI-linearized plasmid pWHE655TREtight-
CpnTCTD, carrying the C-terminal domain of the channel pro-
tein with necrosis inducing toxin (CpnTCTD) characterized in
Mycobacterium tuberculosis (8) (Figures 1A–C), and stable trans-
fectants were selected by limited dilution in the presence of
1500µg/ml G418. Individual subclones were cultured in 48-well
plates and tested for cell death with AxA5/PI staining by FACS
after 24 h of doxycycline (1µg/ml) addition. One out of several
positive clones was chosen for further experiments and named
B16F10-CpnTCTD.
MULTI-PARAMETER CLASSIFICATION OF CELL DEATH BY FLOW
CYTOMETRY
The cell death characterization method analyzing size, granularity,
PS exposure, plasma membrane integrity, mitochondrial mem-
brane potential, and DNA content in a one-tube-measurement
has been thoroughly described elsewhere (9). This method clas-
sifies eight different phases of cell death. Briefly, the harvested
cells were incubated for 30 min at room temperature with 400µl
of freshly prepared 4-color staining solution [1.8µg/ml AxA5-
FITC, 100 ng/ml PI, 10 nM DiIC1(5), 1 ng/ml Hoechst 33342]
in Ringer’s solution and subsequently analyzed. Flow cytometry
was performed with a Gallios cytofluorometer (Beckman Coulter,
Fullerton, CA, USA). Excitation of FITC and PI was at 488 nm, the
FITC fluorescence was detected with the FL1 sensor (525/38 nm
BP), the PI fluorescence with the FL3 sensor (620/30 nm BP), the
DiIC1(5) fluorescence was excited at 638 nm and detected with
the FL6 sensor (675/20 nm BP), and the Hoechst 33342 fluores-
cence was excited at 405 nm and detected with the FL9 sensor
(430/40 nm BP). Electronic compensation was applied to reduce
bleed-through fluorescence. Data analysis was performed with
Kaluza software version 2.0 (Beckman Coulter, Fullerton, CA,
USA). Cells were classified according to their location in the for-
ward scatter (FSc; size) vs. side scatter (SSc; granularity) dot plot
and their staining patterns in the FL1 vs. FL3 and FL6 vs. FL9 dot
plots (Figure 2A).
CELL DEATH INDUCTION
Cell death was induced by (1) doxycycline in vitro (5–10µg/ml)
for expression of the cell death inducing proteins tBid, revCasp-3,
and CpnTCTD. (2) Irradiation with ultraviolet light type B (UVB)
at 1.5 mJ/cm2/s. (3) By heat shock (56°C for 30 min).
MEASUREMENT OF INTRACELLULAR REACTIVE OXYGEN SPECIES
Intracellular reactive oxygen species (ROS) levels were assessed
using the redox-sensitive dye 2,7-dichlorofluorescein diacetate (C-
DCFH-DA). At the time points indicated, dying B16F10 cells were
harvested, incubated for 30 min with C-DCFH-DA (10µM) at
37°C in protein-free medium (D0) in the dark. Cells were then
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FIGURE 1 | Conditional expression of death inducing proteins.
(A) Schematic overview of the constructs used to establish the regulatory
system. The vector pWHE644 represents the regulator construct. A human
EF1α promoter constitutively transcribes a tricistronic mRNA. This mRNA
contains the reverse transactivator rtTA2S-M2 (blue arrow), the transsilencer
tTSD-PP (yellow arrow), and a selection marker (puromycin resistance; gray
arrow). Translation of the latter two genes is mediated by internal ribosome
entry sites (IRES; open boxes) from polio-virus (PV) and encephalomyocarditis-
virus (EMCV). The vector pWHE655 contains the response unit used for
stable transfections. It features the target gene (red arrow) driven by the
Tet-responsive promoter TREtight (open box, broken arrow) and flanked by two
repeats each of a 250 bp sequence from the chicken HS4 insulator (blue
triangles). A murine phosphoglycerate kinase 1 promoter (PGK; broken arrow)
drives expression of a gene mediating G418-resistance. PolyA sites in all
vectors are marked by a “⊥.” (B) Schematic representation of the cytotoxic
test proteins. The residues that border the active domains expressed in the
experiment are indicated above their respective closed box. A methionine
added to allow translation is represented by a star. (C) Schematic overview of
the regulatory system. In the OFF-State, a transsilencer (white) binds to the
minimal promoter (open boxes, broken arrow) and actively suppresses
transcription (cross). In the ON-State, doxycycline (blue circles) binds to both
transsilencer and reverse transactivator (black). The former dissociates from,
the latter binds to the minimal promoter and activates transcription (gray
arrow). (D) Response of the regulatory system to different doxycycline
concentrations. The B16F10-tBid transfected cell line was incubated for 24 h
with various concentrations of doxycycline and mortality was measured,
shown for one representative experiment out of three performed.
Concentrations between 5 and 10µg/ml showed the highest extent of cell
death. An additional control at 10µg/ml Doxy with the parental stably
transfected cell line B16F10-644 was included to discard doxycycline toxicity
at higher concentrations as cause of cell death (dark green diamond). Cell
viability at time point “0” is shown as light green diamond.
washed with D10 by centrifugation, co-stained with PI, and ana-
lyzed by flow cytometry. Only PI-negative cells were analyzed and
ROS levels were presented as the mean fluorescence intensity in
the FL1 channel (MFI-FL1). The anti-oxidants N -acetylcysteine
(NAC) and 2-(2,2,6,6-Tetramethylpiperidin-1-oxyl-4-ylamino)-
2-oxoethyl) triphenylphosphonium chloride (mitoTEMPO) were
used at 100µM as indicated.
ALLOGENEIC TUMOR GROWTH MODEL AND IMMUNIZATIONS
The allogeneic tumor growth model consisted of the host mouse
(BALB/c, MHC haplotype H2d) and B16F10 melanoma cells
derived from C57BL/6 mice (MHC haplotype H2b). Specified
amounts of viable cells or dead/dying cells were subcutaneously
(s.c.) implanted in 500µl Ringer’s solution in the right flank using
a syringe with a 25 G needle. The growth of solid melanoma
tumors was registered by direct measurement of width, height,
and depth of the black subcutaneous protuberance with a caliper
for up to a maximum of 40 days. In accordance with the guidelines
for the welfare of animals in experimental neoplasia, the animal
was sacrificed if the mouse tumor volume exceeded more than
10% of the host’s body weight.
In order to evaluate the immune response against implanted
cells, mice were challenged s.c. with 2 million viable cells in the
opposite flank, after immunization as indicated. The use of the
syngeneic host (C57BL/6) as recipient of B16F10 melanoma cell
lines was ruled out because of the aggressiveness of the B16F10
cells, which may cause discomfort and premature death of the
animal. Mice were purchased from Charles River Laboratories
International, Inc., and kept on a standard diet with drinking water
available ad libitum. Experiments were conducted according to the
European principles and local guidelines for care and use of labo-
ratory animals at the Institute of Cell Biology, National Academy
of Sciences of Ukraine, Lviv (10–12).
STATISTICAL ANALYSIS
The software package GraphPad Prism 5.0 was used for graphics
and statistical tests. For comparisons between control and exper-
imental groups, Mann–Whitney U test or two way ANOVA tests
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FIGURE 2 | Six parameter classification by flow cytometry of the cell
death phenotype of dying and dead B16F10 cells. Cell death analysis is
based on morphological features (FSc and SSc), on the exposure of PS
(annexin A5-FITC) and plasma membrane ion selectivity (PI), on the
mitochondrial membrane potential [DiIC1(5)] and on nuclear DNA content
(Hoechst 33342) detected by flow cytometry. Note: after proper gating, up
to eight physiologically different subpopulations can be recorded. Dot plots
exemplarily show B16F10-revCasp-3 cells after 18 h of doxycycline
(5µg/ml) treatment (A). Rapid cell death occurred after 6 h in
tBid-expressing cells and more than 95% cell death was observed after
24 h. In the presence of various caspase inhibitors [z-VAD-fmk,
z-DEVD-fmk (caspase-3 inhibitor) and Ac-LEHD-cmk (caspase-9 inhibitor);
all 50µM], a significant increase in the stressed cell fraction displaying
low-mitochondrial potential was observed (B). Expression of revCasp-3 in
B16F10 cells induced cell death after 24 h in more than 80% of the cells.
z-VAD-fmk (50µM) completely inhibited doxycycline-driven apoptosis.
Note: stressed cells do not arise in this type of cell death
induction (C). Expression of CpnTCTD induced cell death in more than 90%
of the cells after 18 h. Note: primary necrosis was the most common type
of cell death observed and death occurred independently of caspase
activity (50µM z-VAD-fmk) (D). Lethal UVB irradiation (240 mJ/cm2) of
parental B16F10 cells causes a rather slow progressing kind of cell death.
Note: in the presence of z-VAD-fmk (50µM), a significant increase of the
stressed cell fraction displaying low-mitochondrial potential was
observed (E). Heat shock (56°C, 30 min) caused immediate necrosis in
100% of cells independent of caspase activity (F). Displayed are the mean
values from three independent experiments of relative percentages of
each cell phenotype during 48 h of culture (B–F).
were employed as appropriate. Statistical significance was assumed
if p< 0.05.
RESULTS
STABLE Tet-CONTROLLED MOUSE MELANOMA B16F10 SUICIDE CELL
LINES
Subcloned transfected mouse melanoma B16F10 cell lines were
tested for the response of the regulatory system to different doxy-
cycline (doxy) concentrations after 24 h. Mortality rates were
calculated by annexin A5/PI staining and flow cytometry. Con-
centrations around 10µg/ml doxy showed the highest degree of
cell death (Figure 1D).
CELL DEATH INDUCED BY EXPRESSION OF CYTOTOXIC PROTEINS IN
B16F10 CELLS AND MORPHO-PHYSIOLOGICAL CLASSIFICATION OF
DEAD AND DYING TUMOR CELLS BY FLOW CYTOMETRY
Since dying cells may exhibit various biological features that
modulate the immune response, it is necessary to accurately
Frontiers in Immunology | Tumor Immunity November 2014 | Volume 5 | Article 560 | 4
Chaurio et al. Dead cells modulate allograft immunity
characterize the phenotypes and phases of cell death. Employing
a six parameter protocol to characterize the morphological and
physiological features of dying and dead cells, we identified eight
different states of cell death in B16F10 melanoma cells: (1) viable;
(2) stressed; (3) early apoptosis; (4) apoptosis; (5) late apopto-
sis; (6) secondary necrosis; (7) late secondary necrosis; and (8)
primary necrosis or early secondary necrosis (Figure 2A) (9, 13).
This method allows us to closely describe biological features of
death in cell lines expressing cytotoxic proteins. In our test sys-
tem, doxycycline relieves active repression of the promoter by
the tetracycline-dependent transsilencer (tTS) and simultaneously
induces binding of the reverse tetracycline-dependent transactiva-
tor (rtTA) leading to transgene expression of each death-inducing-
protein (Figure 1C). Additionally, the classical death stimuli UVB
irradiation and heat shock were also employed.
Activation of the suicide switch in B16F10-tBid cells with
5µg/ml doxy was followed by very fast and efficient killing. After
6 h, up to 90% of the cells were dead. Approximately 30% of the
cells displayed features typical for initial phases of apoptosis and
the rest of the cells showed a necrotic phenotype, predominantly
early secondary necrosis (Figure 2B). The role of caspases in the
cell death induced by tBid in B16F10 cells was studied by adding
the pan-caspase inhibitor z-VAD-fmk (50µM). Considering the
physiological stringency of this method, treatment with z-VAD-
fmk did not change the fraction of viable cells treated with doxy.
Interestingly, a significant increase in the fraction of stressed cells
was observed for all times points. Stressed cells are defined as cells
with conserved membrane asymmetry, membrane integrity, and
cell morphology, but very low-mitochondrial membrane potential
[DiIC1(5) low] (13). This fraction reached its maximum at 18 h
post-induction with up to 80% of the cells displaying a stressed
phenotype (Figure 2B). In this case, stressed cells can be con-
sidered to be in a “pre-mortal” state, induced by the expression
of tBid and concomitant inhibition of caspases. Stressed cells are
detected efficiently by the six parameter method described above.
tBid death kinetics in the presence of the more specific caspase-
3 and caspase-9 inhibitors were similar to those observed in the
presence of z-VAD-fmk, and showed comparable amounts of dead
cells (Figure 2B).
Expression of revCasp-3 in B16F10 cells induced cell death
after 24 h, albeit more slowly than tBid, with more than 80% of
the cells displaying dead phenotypes (Figure 2C). Early stages of
apoptosis were observed at 12 and 18 h, while late apoptotic and
secondary necrotic stages were more predominant at 24 and 48 h.
As expected, cell death by expression of revCasp-3 was completely
inhibited in the presence of z-VAD-fmk (Figure 2C).
Expression of the necrosis inducing protein CpnTCTD in
B16F10 cells led to cell death after 18 h with more than 80% of the
cells displaying features of primary necrosis (Figure 2D). Early
stages of apoptosis were not detected by the expression of this
protein. In contrast to pro-apoptotic proteins, z-VAD-fmk did not
affect the death phenotype induced by CpnTCTD, suggesting a
caspase-independent type of cell death (Figure 2D).
It is important to note that cell death induced by doxycycline-
controlled expression of the proteins tBid, revCasp-3, and
CpnTCTD did not kill all cells – some cells may have failed to
respond to doxy. In agreement with this assumption, long-term
culture of doxy-treated cells resulted in confluent growth of the
surviving non-responder cells.
The parental cell line B16F10-644 was lethally irradiated with
UVB (240 mJ/cm2). After 6 h, some stressed and early apoptotic
cells were observed. After 12 h, stressed, apoptotic, and some forms
of necrotic cells were present. Secondary necrotic cells increasingly
appeared from 24 to 48 h. The presence of z-VAD-fmk produced
an important increase in the fraction of stressed cells preserving
the fraction of viable cells, as was also observed for cells expressing
tBid (Figure 2E). UVB irradiation caused much slower death in
comparison to that induced by the expression of tBid, revCasp-3,
or CpnTCTD. Importantly, no surviving cells were observed even
when the plates were cultured for 7 days after irradiation.
Cell death by heat shock was studied in the parental cell line
B16F10-644. Cells were incubated at 56°C for 30 min in a water
bath to induce abrupt membrane disruption. More than 98% of
the cells became primary necrotic. No differences were observed
by the addition of z-VAD-fmk (Figure 2F). In summary, the
suicide switch system efficiently induced morpho-physiologically
different forms of tumor cell death.
REACTIVE OXYGEN SPECIES PRODUCTION IN DYING TUMOR CELLS
In order to further characterize the aforementioned forms of cell
death, we measured the ability of the dying cells to produce free
radicals. After addition of doxy to B16F10-revCasp-3 and B16F10-
CpnTCTD cells, a significant, five to sixfold, increase in the produc-
tion of ROS was observed after 6 h and reached its maximum
at 9 h in both cell lines. Interestingly, dying B16F10-CpnTCTD
cells showed the highest accumulation of ROS (12-fold) before
disruption of the plasma membranes occurred (Figure 3). This
response was compromised by the addition of the anti-oxidants
N -acetylcysteine (NAC) and 2-(2,2,6,6-Tetramethylpiperidin-
1-oxyl-4-ylamino)-2-oxoethyl) triphenylphosphonium chloride
(mitoTEMPO). In contrast, B16F10-tBid expressing and UVB-
irradiated dying cells did not produce significant amounts of ROS
up to 12 h after death induction.
GROWTH OF B16F10 CELLS IN THE ALLOGENEIC BALB/C HOST AND
CONCOMITANT IMMUNITY
Tumor growth of the B16F10 cells was studied in BALB/c mice
by implanting four million viable parental B16F10-644 cells s.c.
into their right flanks (viability>90%). Five days later, black solid
tumors were observed beneath the shaved skin. These tumors
reached their maximum size between days 12 and 15 and spon-
taneously regressed thereafter (Figure 4A). In most cases, small
tumors (5–10 mm3) persisted subcutaneously in the animal show-
ing no further change in size. Tumor recurrence was verified by
keeping mice under observation for more than 2 months; no fur-
ther tumor growth was seen during this time period. Since the
tumors are growing in allogeneic hosts, we regard this as allograft
rejection. Metastases were never observed in any organ.
B16F10 is a poorly immunogenic cell line, not able to gen-
erate concomitant immunity in its syngeneic host. Accordingly,
C57BL/6 mice bearing a progressive tumor are not able to elicit a
protective immune response (14). In order to evaluate the immu-
nity in this allogeneic model, mice were implanted s.c. as follows:
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FIGURE 3 | Reactive oxygen species (ROS) production by dying
B16F10 melanoma cells. Cells were induced to die by conditional
expression of the death proteins tBid, revCasp-3, and CpnTCTD or by
UVB irradiation, stained with the ROS sensor DCFH and with PI and
analyzed by flow cytometry (A). Inhibition of ROS production was
performed by treatment with N -acetyl-cysteine (NAC) or mitoTEMPO,
100µM, respectively, and recorded at 9 h after death
induction (B). Mean and SEM values of the mean fluorescence
intensities of FL1 in viable cells (PI-negative) are displayed for different
time points. At least three independent experiments were performed
(Two and one stars indicate statistical significance at the p<0.001 and
p<0.05 levels, respectively).
FIGURE 4 | Growth of B16F10 melanoma cells in the allogeneic host and
concomitant immunity. Four million viable B16F10 cells (VC) were implanted
s.c. in the right flank of BALB/c mice. Mice developed tumors reaching their
maximum size after 2–3 weeks, followed by rejection [(A), black line]. Mice
implanted with 4 million UVB-irradiated cells did not develop primary tumors
[(A), purple line]. After challenge with 2 million viable cells s.c. on the left
flank, those mice bearing primary tumors did not develop secondary tumors
[(B), black line], while mice primarily inoculated with irradiated cells developed
tumors similar to those of the naïve group [(B), purple and green lines,
respectively]. Mean values (n=8) and the SEM are displayed. Time points
showing statistical significance when compared to the group of mice
implanted with VC are highlighted. Two stars and one star indicate statistical
significance at the p<0.01 and p<0.05 levels, respectively. The two way
ANOVA test corrected by Bonferroni was applied in this experiment.
one group was implanted with 4 million viable cells, the sec-
ond group with lethally UVB-irradiated cells. A third group was
injected with Ringer solution (naïve group). After 12 days, all
groups were challenged s.c. with 2 million viable cells in the oppo-
site flank. The black line in Figure 4A shows growth and rejec-
tion of primary tumors derived from 4 million viable cells. Mice
implanted with UVB-irradiated cells showed no growth of primary
tumors (Figure 4A, purple line p< 0.05 compared to the black
line). After challenge, all mice carrying primary tumors rejected
secondary tumors (Figure 4B, black line). In contrast, mice that
had received UVB-irradiated cells supported the growth of sec-
ondary tumors, as the naïve group did (Figure 4B, purple p< 0.05
and green p< 0.01 lines compared to the black line). This obser-
vation suggests the existence of tumor related immunity in the
allogeneic model. We propose to use this system for the evaluation
of host immunity after immunization with dead and dying cells.
ALLOGENEIC RESPONSE ELICITED BY DYING AND DEAD CELLS
The allogeneic implantation of dead and dying tumor cells
in an immune-competent host allows us to evaluate whether
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the mechanism of cell death induces a silent, a tolerogenic, or
an immunogenic cell death by recording the response after a
standardized challenge. A silent type of cell death would not
affect the growth of the allotumor, a tolerogenic type of cell
death would overcome the expected allograft rejection, while an
immunogenic cell death would favor the rejection of the allo-
tumor. The host response against each previously characterized
form of cell death was assessed in 9–11-week-old female BALB/c
(WT) mice immunized with dying/dead B16F10 cells induced to
die by the following stimuli: (1) UVB irradiation; (2) doxycycline-
controlled expression of the death proteins tBid, revCasp-3, and
CpnTCTD; and (3) heat shock. Stably transfected B16F10 cells were
induced to die by adding 10µg/ml doxy to the tissue culture dishes
(150 cm2) at 37°C and 5% CO2 for 5 h. Afterward, UVB irradiation
(240 mJ/cm2) was performed in order to kill the remaining non-
responsive cells. Previous experiments had demonstrated that the
additional UVB irradiation at this time point neither altered the
expression level of the death-inducing proteins nor the kinetics of
the specific death phenotype (Figure S1 in Supplementary Mater-
ial). Sixteen million dying/dead cells were injected s.c. in the right
flank as single immunization dose at day 0. After 10 days, mice
were challenged in the left flank with 2 million viable cells of the
parental cell line B16F10-644. Tumor growth was recorded at days
5, 8, 11, 14, 20, and 30 after challenge (Figure 5A). Viable cells
implanted in naïve BALB/c mice generated tumors that reached
their maximal size after 2 weeks followed by regression, as expected
(Figure 5B, black lines). This group was used as reference cohort.
Mice immunized with UVB-irradiated cells and tBid-
expressing cells developed tumors with sizes similar to that of
the naïve group. This points to a state of unresponsiveness in these
mice (Figure 5B). In contrast, and especially at the days 8, 11, and
14, mice immunized with cells dying because of the expression
of revCasp-3 or CpnTCTD displayed significantly smaller tumors
than naïve mice (Figure 5B; p< 0.05).
In order to estimate the total tumor mass generated for each
immunization cohort, an analysis based on the cumulative area
under the curve (integral) was performed. Figure 5C shows the
total amount of tumor mass developed in the allogeneic host
for each cohort. Mice immunized with UVB-irradiated cells or
with cells that express tBid developed similar tumor masses. Con-
versely, mice immunized with dying/dead cells because of revCasp-
3 and CpnTCTD expression developed significantly smaller tumor
masses (Figure 5C). Based on these observations, we considered
UVB irradiation and over-expression of tBid as silent or tolero-
genic forms of cell death. Accordingly, over-expression of revCasp-
3 and CpnTCTD induced immunogenic cell death. At best, only a
weak immunogenic response was elicited by cells treated with heat
shock reflecting that the rapid induction of necrosis by heat shock
has the inevitable disadvantage of diffusion of danger signals to
the medium. One major advantage of doxy-controlled induction
of cell death, in particular necrotic cell death, is the achievement of
a necrotic phenotype without physical interaction with the cells.
Interestingly, those forms of death showing significant ROS
production upon in vitro stimulation died in an immuno-
genic fashion (Figure 5D). To more closely address the role
of ROS production in the development of allo-responses, we
treated ROS-producing CpnTCTD-expressing dead and dying cells
with the anti-oxidant NAC before immunization. This treatment
resulted in the amelioration of the allo-response against the
challenge; however, it was not statistically significant (Figure S2
in Supplementary Material).
DISCUSSION
Conventional studies characterizing cell death are based on PS
exposure and ion selectivity of the plasma membrane (AxA5 and
PI staining) (15–17). These methods have traditionally classified
cells as viable, apoptotic, or necrotic. However, because of the
important role of the mitochondria as modulator of cell death, a
concomitant analysis that monitors changes in the mitochondrial
membrane potential is required. On the one hand, mitochon-
dria play a role during apoptosis through the release of several
apoptogenic proteins located in the inter-membrane space and,
consequently, in apoptosome formation (18). On the other hand,
mitochondria determine the outcome of many ATP-dependent
cell physiological processes and, thus, are important for necrotic
cell death. In this work, we used a modified staining and cytofluo-
rometry protocol for a more detailed analysis of tumor cell death
induced by various stimuli. Its major advantage is the possibil-
ity to classify at least eight different stages of cell death (viable,
stressed, early/medium/late apoptosis, early/late secondary necro-
sis, primary necrosis) in a fast and reliable one-tube assay. A
similar method employing a four-color staining for evaluation of
PS exposure (AxA5-FITC), plasma membrane integrity (PI), mito-
chondrial membrane potential (JC-1), and nuclear DNA content
(Hoechst 33342) was reported (19). However, a clear classification
and identification of different types and stages of cell death was
missing in that report.
Usually, standard methods are employed to generate dead cells
for immunization experiments, e.g., in vitro induction of apopto-
sis/necrosis in cells and their subsequent injection into the mouse.
This approach allowed the dissection of important modulatory
effects of apoptotic cells in living multicellular organisms, as well
as the employment of adjuvants in cell-based immunization mod-
els (20–22). However, the manipulation of dying and dead cells ex
vivo has the disadvantage of their rapid progression from apoptosis
to secondary necrosis and the concomitant decay and dilution of
labile and short-range active immunomodulatory signals, respec-
tively. In order to avoid the aforementioned limitations, we have
established a conditional doxycycline-dependent expression sys-
tem able to trigger various types of tumor cell death. Vectors
harboring cDNAs encoding for tBid, revCasp-3, and CpnTCTD
were stably transfected into B16F10 melanoma cells.
tBid is a major pro-apoptotic protein activated in both extrin-
sic and intrinsic pathways and is an important connector between
these canonical apoptosis pathways. tBid translocates to the mito-
chondria promoting mitochondrial outer membrane permeabi-
lization (MOMP), a process involving self-assembly of activated
BAX and BAK into transmembrane pores, which can be inhibited
by anti-apoptotic BCL2 family proteins (23–25). Moreover, tBid
accumulation determines the timing of MOMP (26). In addition
to cytochrome c, tBid induces the release of further mitochon-
drial death effectors that promote caspase-independent apoptosis
and induce mitochondrial remodeling. All these processes result
in loss of the mitochondrial membrane potential, blocking of ATP
synthesis and, consequently, loss of function of ATP-dependent
transporters.
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FIGURE 5 | Immune response against dead or dying allogeneic tumor
cells. BALB/c mice (n=5) were immunized in the right flank s.c. (single dose)
with B16F10 dying/dead cells. After 10 days, mice were challenged s.c. in the
left flank with 2 million viable cells of the parental cell line B16F10-644. Tumor
growth was monitored for 30 further days (A). Cell death was induced by UVB
irradiation; heat shock; doxycycline-controlled expression of death proteins
tBid, revCasp-3, and CpnTCTD. Displayed are the mean values (n=5) of relative
tumor volumes and SEM [(B), *p<0.05 after Mann–Whitney U test] and the
integral of tumor size [(C), total tumor mass]. Inverse association between
ROS production and total tumor mass developed in the allogeneic host (D).
Over-expression of tBid can be considered to represent a harsh
stimulus that quickly drives cells toward advanced stages of the
apoptotic process with metabolic collapse leading to an early loss
of plasma membrane integrity and rupture. We have defined this
particular state of early loss of plasma membrane integrity as
early secondary necrosis. It clearly differs from primary necro-
sis because of its susceptibility to inhibition by caspase inhibitors.
Similar stimuli have already been reported to induce necrosis (27–
29). This new cell death state may have particular relevance under
clinical conditions like treatment with chemotherapy in cancer.
Our cell death classification method allowed the identification of
a further new stage in the process of dying, which we propose to
refer to as stressed cells. The latter were observed especially when
the over-expression of tBid was induced in the presence of z-VAD-
fmk. Stressed cells show low-mitochondrial potential, suggesting
the presence of MOMP and severe damage to the mitochondrial
membranes in the absence of any further signs of apoptosis. The
pan-caspase inhibitor z-VAD-fmk efficiently blocks certain types
of apoptosis. In consequence, the common hallmarks of the execu-
tion phase of apoptosis, like PS exposure, cell shrinkage, and DNA
fragmentation are inhibited. The cells appear viable although they
are actually dead because of severe damage of the mitochondrial
membranes after over-expression of tBid, which directly activates
the mitochondrial pathway.
Compared to the expression of tBid, melanoma cells dying after
the expression of revCasp-3 showed slower cell death kinetics.
Twenty four hours of expression of revCasp-3 were required to
reach a similar degree of cell death. Caspase-3 is the major caspase
activated during the execution phase of apoptosis (30). However,
expression of revCasp-3 does not directly act on the mitochondria
to induce MOMP. Caspase-3 needs to cleave sufficient MOMP-
inducing substrates like Bid to tBid before MOMP and cell death
can occur by a feed-forward amplification loop (31). Additionally,
caspase-3 can then enter the mitochondria and cleave specific sub-
strates of the electron transfer chain, which will ultimately result
in mitochondrial uncoupling and loss of membrane potential.
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Addition of z-VAD-fmk to revCasp-3 expressing cells inhibited up
to 95% of the cell death occurring (more than 90% viable cells).
These results demonstrate that, after blocking caspases, damage to
mitochondria and to cell morphology and physiology was effec-
tively inhibited, as confirmed by the lack of appearance of large
numbers of stressed cells in Figure 2C.
Induction of apoptosis by UVB irradiation has been recognized
to be a complex process involving a variety of independent path-
ways. There are at least two major mechanisms involved in apop-
tosis induced by UVB: (1) DNA damage; UVB induces two types
of lesions in chromosomal DNA, photoproducts, and cyclobutane
pyrimidine dimers (CPD), the latter being the predominant ones
(32). (2) Cell death receptor activation; UVB is able to directly
activate cell surface receptors (i.e., CD95/Fas and TNF receptor-1)
by inducing receptor trimerization and clustering without ligand
interaction (33–35). In our study, B16F10 melanoma cells were
lethally irradiated with 240 mJ/cm2 UVB applied as a single dose.
Lower doses failed to completely kill the cells (data not shown). In
the 24 h period following irradiation, we observed slow cell death
kinetics mainly characterized by the presence of stressed (mito-
chondrial damage) and early secondary necrotic cells (membrane
disruption and DNA preservation). Substantial amounts of late
apoptotic and late secondary necrotic cells were only observed
after 48 h.
Cells dying by UVB irradiation in the presence of z-VAD-fmk
also showed a significant increase in the fraction of stressed cells,
indicating a blockade of the apoptotic execution phase, which
may be responsible for the preservation of the cell’s morphol-
ogy. In the presence of z-VAD-fmk, the percentage of viable cells
did not change significantly, showing that inhibition of caspases
cannot rescue cells from death. This observation challenges pre-
vious own and foreign reports presenting effective inhibition of
UVB-induced apoptosis by z-VAD-fmk (36–38). Employing our
multiparametric analysis, we here put forward a more detailed
characterization of cell death phenotypes induced by several stim-
uli. We conclude that UVB mainly acts in B16F10 cells by triggering
the intrinsic mitochondrial death pathway.
Necrosis is a cellular state that follows acute injuries, sudden
anoxia, or extreme stimuli (heat, irradiation, toxins, mechanical,
or oxidative stress) and, according to that, it can be viewed as a
violent kind of cell death. Conventional methods used to induce
necrosis in immunological studies applied heat shock at 56°C
or alternating cycles of freeze–thawing. In this work, we present
an alternative approach expressing a necrosis inducing protein
(CpnTCTD) via a doxy-dependent inducible expression system.
CpnT is a novel outer membrane protein of M. tuberculosis con-
taining a C-terminal domain that is cytotoxic when expressed in
eukaryotic cells (8). It has been suggested to be required for the
escape of M. tuberculosis from macrophages allowing subsequent
bacterial dissemination. However, how CpnTCTD induces necrosis
is still mechanistically elusive. Six hours after the addition of doxy,
a significant fraction of stressed cells was observed. This suggests
loss of the mitochondrial membrane potential and mitochondrial
damage. Twelve and 18 h after the addition of doxy, more than
50 and 80% of the cells were primary necrotic, respectively. Only
after 48 h post-doxy addition, was DNA degradation observed.
The decreased DNA content of the latter mimics some features of
secondary necrotic death. However, DNA degradation occurred
in cells that had already lost their membrane integrity. The cells
should, therefore, be referred to as post-necrotic and not as post-
apoptotic. The passive influx of DNA degrading enzymes and/or
Ca2+ most likely causes the chromatin degradation observed in
necrotic cells. Expression of the CpnTCTD protein in the presence
of z-VAD-fmk showed the same phenotype as those not treated
with the inhibitor, arguing for a caspase-independent type of cell
death. A classical method to induce necrosis is a heat shock at
56°C for 30 min. As expected, cells became necrotic immediately
after heating. This process was also not affected by the presence of
z-VAD-fmk, suggesting that caspases were not required for death
induced by this kind of heat shock.
Most anti-cancer therapies, like chemotherapy and radiother-
apy, aim to induce cancer cell death. However, a central problem
is to understand how the immune system determines whether
cell death elicits immunogenic, tolerogenic, or silent responses. It
has been reported that type and/or phase of cell death affect the
immune response (3, 39). For example, cells treated with antra-
cyclines, oxaliplatin, or UVC light develop a kind of endoplasmic
reticulum (ER) stress response that involves recruitment of several
actors of the apoptotic pathway and contributes to the expo-
sure of calreticulin, which represents an important determinant
of immunogenic cell death (40–42).
In order to evaluate whether a certain type of cell death is
immunogenic or tolerogenic/silent, an allogeneic murine graft
rejection model was employed. The s.c. tumor progression in
BALB/c mice was monitored after immunizing the host with vari-
ous kinds of dying/dead cells. We hypothesized that immunization
with tolerogenic or silent forms of cell death would overcome
or not affect the natural host immunity allowing tumor devel-
opment in BALB/c mice, respectively. In contrast, immunogenic
cell death would result in faster and more efficient rejection and
persistent immunity (3, 43–47). Syngeneic implantation of viable
B16F10 cells in C57/Bl6 mice reportedly resulted in high mortality
because of the potent carcinogenicity making it difficult to evaluate
the immune response against various kinds of cell death (48, 49).
The allogeneic model, instead, allows us to compare the immune
modulatory effects of cell death forms without compromising the
welfare of the host (10–12).
Immune responses elicited by dying/dead cells in BALB/c mice
were dependent on the death stimulus applied to the vaccine.
Mice implanted with viable melanoma cells transiently produced
primary tumors, but never developed secondary tumors after re-
challenge (100% rejection). In contrast, mice immunized with
irradiated cells supported the growth of secondary tumors similar
to the naïve cohort. In order to explore this effect thoroughly, mice
were challenged after having been immunized with dying/dead
cells killed by various mechanisms.
Expression of the necrosis inducing protein domain CpnTCTD
in a B16F10 cell-based vaccine resulted in the most immunogenic
type of cell death. Unexpectedly, expression of the pro-apoptotic
constitutively active form of caspase-3 (revCasp-3) also induced
a strongly immunogenic type of cell death. Massive apopto-
sis induced by the regulated expression of revCasp-3 in already
implanted syngeneic tumors has been reported to be immunogenic
(50). Expression of caspase-3 induced a high percentage of necrotic
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cell death (early and late secondary necrosis). Heat-necrotized
cells, which display membrane disruption already before injec-
tion, exhibited poor immunogenicity. This points to short-lived
necrotic cell-derived signaling molecules, which would not be
active anymore in the vaccine that had been necrotized before
injection. Summarizing, in our model the time of appearance of
membrane disruption in B16F10 cells did not correlate with the
type of immune response the cells elicited. Noteworthy, UVB-
irradiated cells showed the lowest percentage of necrotic cells
and failed to trigger immunity. tBid-expressing cells and UVB-
irradiated cells used for immunization clearly behaved silently and
allowed the growth of allogeneic tumors, despite the presence of
high levels of necrotic cells, as in naïve animals.
The unresponsiveness observed in our system cannot be
explained solely by the exposure of PS. Similarly, DAMPs released
or expressed after disruption of the plasma membrane are also not
sufficient to explain the immunogenicity observed in our model.
Therefore, we looked for common features of the two “silent”
types of cell death, over-expression of tBid and UVB irradiation,
and of the two immunogenic types of cell death, over-expression
of revCasp-3 and CpnTCTD. The common denominator in both
cases is the prominent role of the mitochondria in the execution
of death (39).
In our system, activation of the intrinsic pathway either by the
recombinant expression of cleaved active Bid or by UVB irradi-
ation may have caused death without relevant ROS production
during the time frame the cells were employed for immunization
(3–9 h after doxy treatment). Although some caspase-3 activity is
to be expected in both tBid- and UVB-induced death, this was
not enough to secondarily generate ROS. In contrast, downstream
expression of revCasp-3 and CpnTCTD may have caused death by
activation of terminal effector mechanisms excluding the involve-
ment of mitochondria. Therefore, we assume that in the revCasp-3
and CpnTCTD cases, execution of cell death starts before mito-
chondrial function is severely compromised. After over-expression
of revCasp-3, MOMP formation is induced allowing access of
caspase-3 to the mitochondrial inter-membrane space, cleaving
specific substrates in the complex I of the electron transport
chain (like p75 NDUSF1) (51, 52). As a consequence, the elec-
tron transport is disrupted, and ROS is generated. In contrast,
tBid expression causes severe damage to the mitochondria mea-
sured as a fast loss of the mitochondrial potential, suggesting fast
MOMP formation thereby destroying electron transport abruptly.
We propose that ROS can be produced in cells overexpressing
revCasp-3 and possibly CpnTCTD because mitochondrial activity
is not severely affected by an intrinsic death stimulus. Ongoing
cell death in the presence of functioning mitochondria would be
important for intracellular ROS accumulation. Free radicals gener-
ated in this context may induce considerable stress in the ER, which
has been associated with immunogenicity of the dying cells (3).
We suggest that intracellular accumulation of ROS intermedi-
ates may play a critical role in the generation of DAMPs affecting
the ongoing allogeneic immune response. For example, oxida-
tive damage to DNA enhances its immune-stimulatory capabilities
once processed by the immune system (53). Avoiding intracellu-
lar accumulation of ROS by a selective manipulation of mito-
chondrial functionality before killing cells is a possible option
to down-regulate the subsequent immune response. Reversely,
conserving mitochondrial function as long as possible during
cancer cell killing may increase the immunogenicity, if this is
wanted.
Although NAC significantly inhibited ROS production in
CpnTCTD-expressing cells in vitro (Figure 3), the employment
of this anti-oxidant during cell death induced by the expression
of CpnTCTD was not sufficient to abrogate their immunogenic-
ity in our allo-immunization model. Interestingly, the addition of
the specific mitochondrial ROS scavenger mitoTEMPO induced
significant inhibition of ROS production in B16F10-revCasp-3
and B16F10-CpnTCTD dying cells in vitro arguing for an impor-
tant role of the mitochondria in ROS production. Since inhibition
in vitro by NAC or mitoTEMPO was partial, ROS may be addi-
tionally produced in other cellular compartments like the ER.
Noteworthy, it was demonstrated in yeasts that mitochondrial
dysfunction indirectly induces ROS production in the ER by a
novel mechanism mediated by suppression of the endoplasmic
reticulum-associated degradation (ERAD) pathway (54, 55). In
line with this, ER stress may result in increased cytoplasmic Ca2+
concentrations and immunogenic cell death (56). Further investi-
gation addressing the source and localization of ROS in these cells
is needed to elucidate the exact role of ROS production during cell
death and its immunological consequences, especially in in vivo
models.
We speculate that some of the mechanisms observed in this
manuscript might also work in patients with tumors,during tumor
therapy and in some syngeneic tumor models. However, the appli-
cation of tumor vaccines in human beings has, so far, been less
successful. The association between intracellular ROS accumula-
tion in dying cells and allogeneic tumor rejection may have the
potential to intentionally shape anti-tumor immunity.
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Figure S1 | UVB irradiation of B16F10 cells after doxycycline treatment. In
order to rule out that an additional irradiation step interferes with the type of cell
death induced by specific expression of the respective cytotoxic protein in the
cell lines B16F10-tBid, B16F10-revCasp-3, and B16F10-CpnTCTD, cells were
induced to die with doxycyline (5µg/ml) and irradiated with a single dose of
240 mJ/cm2 UVB at different time points (t =4 h, t =5 h, t =6 h, and t =7 h).
Eighteen hours after doxycycline addition (t 0), the cells were harvested by
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trypsinization and analyzed by FACS for PI staining. Cells killed solely by UVB or
doxycycline were used as controls. Blue bars show death induced by irradiation
alone. Red bars show death by doxycycline-regulated expression of each
cytotoxic protein alone. Green bars show the combined effect of cytotoxic
protein expression plus irradiation at different time points. Note that cells
irradiated 4, 5, 6, and 7 h after doxycycline addition (green bars) died to the
same extent as cells killed by doxycycline alone (red bars).These results
suggest that after 4 h of incubation with doxy, the additional irradiation step did
not significantly affect the degree of doxycycline-induced cell death despite of
the additional damage caused by the irradiation. We, therefore, assumed that
after 4 h the cytotoxic protein expression is sufficient to induce cell death as it
would happen without irradiation. Irradiation at earlier time points significantly
impaired doxycycline-regulated cell death (data not shown). This procedure
ensured killing of the doxycycline-resistant cells in primary grafts in order to
consequently avoid complications caused by proliferative signals emitted from
the dying cells acting on the surviving tumor cells.
Figure S2 | Immune response against allogeneic dead and dying cells in
the presence of the ROS inhibitor NAC. BALB/c mice were immunized in the
right flank s.c. (single dose) with dying B16F10 cells expressing CpnTCTD (red
lines/bars) or dying B16F10 cells expressing CpnTCTD in the presence of the ROS
inhibitor n-Acetylcysteine (NAC, green lines/bars). Displayed are the mean
values (n=7) of the relative tumor volumes and their SEMs and the respective
integral of tumor size (total tumor mass) that was obtained in mice challenged
s.c. in the left flank with 2 million VC of the parental cell line B16F10-644 10 days
after immunization. The Mann–Whitney U test was applied to compare groups.
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